



**University of
Zurich^{UZH}**

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2008

Disruption of the blood-brain barrier by intra-arterial administration of papaverine: a technical note

Platz, J ; Baráth, K ; Keller, E ; Valavanis, A

Abstract: INTRODUCTION: Various endovascular techniques can be used to treat cerebral vasospasm after aneurysmal subarachnoid haemorrhage (SAH) including intra-arterial administration of vasodilator drugs such as papaverine or nicardipine and balloon dilatation of the affected vessel segment. Papaverine is known to have side effects, and we report a possible new one. MATERIALS AND METHODS: After the treatment of cerebral vasospasm in a SAH patient by intra-arterial administration of papaverine into the left posterior cerebral artery, severe mesencephalic extravasation of blood and contrast media was detected. RESULTS: After reviewing the literature, the authors conclude that interruption of the blood-brain barrier by papaverine most likely combined with a secondary hyperperfusion phenomena, and perhaps a direct toxic effect on brain tissue was the mechanism of this major complication. CONCLUSION: In treating vasospasm in areas with a high density of perforating arteries, especially in the posterior circulation, papaverine should be used cautiously because a safe regimen has yet to be established. In this situation, alternative agents such as calcium channel blockers could be considered, but evidence-based data are still missing.

DOI: <https://doi.org/10.1007/s00234-008-0455-x>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-6608>

Journal Article

Published Version

Originally published at:

Platz, J; Baráth, K; Keller, E; Valavanis, A (2008). Disruption of the blood-brain barrier by intra-arterial administration of papaverine: a technical note. *Neuroradiology*, 50(12):1035-1039.

DOI: <https://doi.org/10.1007/s00234-008-0455-x>

Disruption of the blood–brain barrier by intra-arterial administration of papaverine: a technical note

Johannes Platz · Krisztina Baráth · Emanuela Keller ·
Anton Valavanis

Received: 8 April 2008 / Accepted: 27 August 2008 / Published online: 13 September 2008
© Springer-Verlag 2008

Abstract

Introduction Various endovascular techniques can be used to treat cerebral vasospasm after aneurysmal subarachnoid haemorrhage (SAH) including intra-arterial administration of vasodilator drugs such as papaverine or nicardipine and balloon dilatation of the affected vessel segment. Papaverine is known to have side effects, and we report a possible new one.

Materials and methods After the treatment of cerebral vasospasm in a SAH patient by intra-arterial administration of papaverine into the left posterior cerebral artery, severe mesencephalic extravasation of blood and contrast media was detected.

Results After reviewing the literature, the authors conclude that interruption of the blood–brain barrier by papaverine most likely combined with a secondary hyperperfusion phenomena, and perhaps a direct toxic effect on brain tissue was the mechanism of this major complication.

Conclusion In treating vasospasm in areas with a high density of perforating arteries, especially in the posterior circulation, papaverine should be used cautiously because a safe regimen has yet to be established. In this situation,

alternative agents such as calcium channel blockers could be considered, but evidence-based data are still missing.

Keywords Intra-arterial administration of papaverine · Vasospasm · Subarachnoid hemorrhage · Complication of treatment

Introduction

Cerebral vasospasm remains a major problem in the subacute treatment of subarachnoid haemorrhage (SAH). Angiographically detectable in about 70% of patients, it leads to delayed neurological deficits in 20% to 30%, with 7% of patients dying [1]. Various endovascular techniques were developed to treat vasospasm including intra-arterial administration of papaverine (IAP), which was introduced in 1992 [2–4]. Papaverine leads to an improvement of cerebral blood flow (CBF) by dilating the proximal, intermediate, and distal cerebral arteries [5–8]. As a result, oxygen supply is increased, preventing further lactate brain acidosis and facilitating recovery [9, 10].

Angiographic improvement is achieved in up to 96% and clinical improvement in 33% to 80% [5, 10–12]. Here, we describe a new complication of IAP.

Case presentation

A ruptured anterior communicating artery aneurysm was clipped in a 67-year-old woman suffering SAH (Fig. 1a,b). Seven days later, vasospasm was suspected on transcranial duplex ultrasound. A computed tomography (CT) perfusion scan showed changes typical of vasospasm in the left posterior cerebral artery (PCA) territory (Fig. 1c,d [13–15]), and digital subtraction angiogram confirmed vasospasm in

J. Platz · K. Baráth · A. Valavanis
Institute of Neuroradiology, University Hospital Zürich,
Zürich, Switzerland

E. Keller
Department of Neurosurgery, University Hospital Zürich,
Zürich, Switzerland

J. Platz (✉)
Neurochirurgische Klinik, Universitätsklinikum Frankfurt am Main,
Schleusenweg 2-16,
60528 Frankfurt am Main, Germany
e-mail: platz@med.uni-frankfurt.de




Fig. 1 **a** CT on admission, showing excessive SAH (Fisher grade 3, Hunt & Hess grade 5). **b** Aneurysm of the anterior communicating artery detected in computed tomography angiography. **c**, **d** CT perfusion:

Prolonged time to peak (**c**) and normal cerebral blood volume (**d**) in the left PCA territory, while CBF was slightly decreased without new infarctions in cranial computed tomography (data not shown)

the left P1 segment (Fig. 2a,b). IAP was indicated [16], and a FastTracker 10 catheter was easily placed at the origin of the left PCA and an initial infusion of 150 mg papaverine (diluted to 0.3%) made over 25 min without improvement in the vessel diameter (Fig. 2c). Therefore, another 150 mg papaverine was administered, and the vasospasm relieved (Fig. 2d).

Following the infusion, the left pupil was found to have dilated, though intracranial pressure (ICP) remained

normal. An immediate brain CT showed a new lesion in the left mesencephalon without significant mass effect or crossing of the midline (Fig. 3).

The patient was referred to the intensive care unit. As vasospasm worsened, hypothermia and barbiturate coma were initiated [17], but no further endovascular interventions were undertaken. Follow-up CT scans showed progressive infarctions, and resolution of the mesencephalic hyperdensity resolved. The patient died on day 25.




Fig. 2 **a** Initial angiogram showing normal vessel diameters. **b** Vasospasm of the left P1 segment before IAP. **c** Control after administration of 150 mg of papaverine showing no relevant change in the vessel caliber. **d** Final angiographic control after administration of a total of 300 mg showing no hints for a vessel rupture




Fig. 3 Immediately after IAP, a new hyperdense lesion is noted in the left mesencephalon without crossing of the midline (**b**, **c**, **d**) when compared to the CT before the procedure (**a**). Note the absence of a significant mass effect as one would expect in the case of hemorrhage. Furthermore, no vessel rupture or extravasation of contrast dye was noted during the procedure. The Hounsfield units (55 to 110) of more than 100 suggest that also part of the contrast dye contributes to the extravasation

Discussion

Papaverine acts directly on vascular smooth muscle cells by inhibiting cyclic adenosine monophosphate and cyclic guanosine 3,5 monophosphate leading to vasodilatation [18]. We have routinely performed IAP, with good results, since 1993 [4, 9, 16, 17, 19]. The incident reported here with a new intraparenchymal hyperdensity without mass effect has not been observed before.

Three mechanisms may play a role. First, evidence from animal studies suggests that infusion of papaverine may lead to a disruption of the blood–brain barrier (BBB) with extravasation of blood and radiographic contrast agents [20]. Another group noted that, in higher concentrations, papaverine may damage luminal endothelial and smooth muscle cells because of its high acidity [21]. Besides, high concentrations of the drug may lead to its precipitation and subsequent microembolization [22–24]. Second, because IAP locally increases CBF through vasodilatation [7, 25], hyperperfusion after treatment may facilitate extravasation [12], especially in the presence of a damaged BBB. Third, a direct neurotoxic effect of papaverine seems possible. Smith et al. detected changes in the gray matter and in the neurological status of patients after treatment with IAP. Based on their imaging data and a pathological examination, they suggest that IAP leads to a blockade of mitochondrial respiration and inhibition of the Krebs cycle [26]. Considering the almost immediate effect in our case, this mechanism does not seem to have played an important role but may have contributed to the devastating outcome.

Although dilutions of 0.6% papaverine have been administered in humans without complications [27], this concentration might easily be exceeded locally in the presence of vasospasm. A distal spastic vessel segment may reduce the physiological dilution of papaverine, and an accumulation of the drug in proximal perforators may cause damage of the vessel wall [21].

Although we cannot exclude preexisting ischemia in the affected area making the tissue more vulnerable, the absence of clinical symptoms or hypodensities on CT before treatment makes this unlikely (Fig. 3a), and the findings on CT perfusion were not typical for irreversible infarction [28]. In circumstances similar to our patient, McAuliffe et al. reported a patient who died due to a hemorrhage in the basal ganglia immediately after IAP in this territory. The authors excluded vessel rupture as the cause [29].

The dose and infusion rate of papaverine remain unsolved, and published guidelines are lacking. In the literature, 150 to 300 mg papaverine administered per vessel segment seems to be a generally accepted dose [1, 3, 7, 9–11, 16, 22, 30–35]. However, reported doses vary widely from a few milligrams [2, 5] to more than 400 mg

[26, 27, 32, 35]. For the posterior circulation, only few cases have been published [9, 27, 32]. Furthermore, recommended infusion rates vary substantially between 15 to 60 min for 300 mg [3, 6, 7, 22, 26, 30–34]. In our case, either the dose (300 mg) or the rate (50 min) or both seem to have been inappropriate. Therefore, we recommend using less than 300 mg per segment in the posterior circulation at even slower infusion rates than usual.

There are alternative drugs for the endovascular treatment of vasospasm. Most of them are calcium channel antagonists, e.g., nimodipine or nicardipine. But there are only small series reported in the literature with success rates ranging from 43% to 100% and from 29% to 89% as measured by increase in vessel diameter and neurological improvement, respectively. Adverse effects, such as circulatory events or, infrequently, ICP increase, were described in 0% to 33% of patients [1, 36–38]. Compared to papaverine, a direct neuroprotective effect of nimodipine has been postulated [1], while the problem of a transient treatment effect remains [39].

Conclusion

We assume that our case was the result of a combination of factors in which pathological hemodynamics due to vasospasm caused an unexpected high concentration of papaverine in perforator vessels, leading to BBB disruption with extravasation of blood and contrast media, possibly facilitated by secondary hyperperfusion. Therefore, we suggest a very cautious use of the drug especially in areas with numerous perforators proximal to a vasospastic segment. Safe infusion rates and dosage still need to be established. On the other hand, further studies need to prove the potential advantage of alternative drugs such as calcium channel antagonists.

Conflict of interest statement We declare that we have no conflict of interest.

References

1. Sayama CM, Liu JK, Couldwell WT (2006) Update on endovascular therapies for cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. *Neurosurg Focus* 21:E12 doi:10.3171/foc.2006.21.3.12
2. Kaku Y, Yonekawa Y, Tsukahara T, Kazekawa K (1992) Super-selective intraarterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. *J Neurosurg* 77:842–847
3. Kassell NF, Helm G, Simmons N, Phillips CD, Cail WS (1992) Treatment of cerebral vasospasm with intra-arterial papaverine. *J Neurosurg* 77:848–852

4. Valavanis A (1993) Recent advances in the endovascular treatment of cerebral vasospasm and intracranial aneurysms. *Crit Rev Neurosurg* 3:115–125
5. Minami H, Kuwamura K, Tamaki N (2001) Intraarterial infusion of papaverine and change of cerebral hemodynamics in symptomatic cerebral vasospasm. *Kobe J Med Sci* 47:169–179
6. Liu JK, Tenner MS, Gottfried ON, Stevens EA, Rosenow JM, Madan N et al (2004) Efficacy of multiple intraarterial papaverine infusions for improvement in cerebral circulation time in patients with recurrent cerebral vasospasm. *J Neurosurg* 100:414–421
7. Vajkoczy P, Horn P, Bauhuf C, Munch E, Hubner U, Ing D et al (2001) Effect of intra-arterial papaverine on regional cerebral blood flow in hemodynamically relevant cerebral vasospasm. *Stroke* 32:498–505
8. Keller E, Wolf M, Martin M, Yonekawa Y (2001) Estimation of cerebral oxygenation and hemodynamics in cerebral vasospasm using indocyanine green dye dilution and near infrared spectroscopy: a case report. *J Neurosurg Anesthesiol* 13:43–48 doi:10.1097/00008506-200101000-00008
9. Fandino J, Kaku Y, Schuknecht B, Valavanis A, Yonekawa Y (1998) Improvement of cerebral oxygenation patterns and metabolic validation of superselective intraarterial infusion of papaverine for the treatment of cerebral vasospasm. *J Neurosurg* 89: 93–100
10. Schuknecht B, Fandino J, Yuksel C, Yonekawa Y, Valavanis A (1999) Endovascular treatment of cerebral vasospasm: assessment of treatment effect by cerebral angiography and transcranial colour Doppler sonography. *Neuroradiology* 41:453–462 doi:10.1007/s002340050784
11. Andaluz N, Tomsick TA, Tew JM Jr, van Loveren HR, Yeh HS, Zuccarello M (2002) Indications for endovascular therapy for refractory vasospasm after aneurysmal subarachnoid hemorrhage: experience at the University of Cincinnati. *Surg Neurol* 58:131–138 doi:10.1016/S0090-3019(02)00789-9
12. Smith TP, Enterline DS (2000) Endovascular treatment of cerebral vasospasm. *J Vasc Interv Radiol* 11:547–559 doi:10.1016/S1051-0443(07)61605-4
13. Wintermark M, Ko NU, Smith WS, Liu S, Higashida RT, Dillon WP (2006) Vasospasm after subarachnoid hemorrhage: utility of perfusion CT and CT angiography on diagnosis and management. *Am J Neuroradiol* 27:26–34
14. Moftakhar R, Rowley HA, Turk A, Niemann DB, Kienitz BA, Van GJ et al (2006) Utility of computed tomography perfusion in detection of cerebral vasospasm in patients with subarachnoid hemorrhage. *Neurosurg Focus* 21:E6 doi:10.3171/foc.2006.21.3.6
15. Lad SP, Guzman R, Kelly ME, Li G, Lim M, Lovbald K et al (2006) Cerebral perfusion imaging in vasospasm. *Neurosurg Focus* 21:E7 doi:10.3171/foc.2006.21.3.7
16. Fandino J, Schuknecht B, Yuksel C, Wieser HG, Valavanis A, Yonekawa Y (1999) Clinical, angiographic, and sonographic findings after structured treatment of cerebral vasospasm and their relation to final outcomes. *Acta Neurochir (Wien)* 141:677–690 doi:10.1007/s007010050362
17. Keller E, Krayenbuhl N, Bjeljac M, Yonekawa Y (2005) Cerebral vasospasm: results of a structured multimodal treatment. *Acta Neurochir Suppl (Wien)* 94:65–73 doi:10.1007/3-211-27911-3_11
18. Bolton TB (1979) Mechanisms of action of transmitters and other substances on smooth muscle. *Physiol Rev* 59:606–718
19. Andreon A, Valavanis A (1994) Endovascular treatment of cerebral vasospasm following subarachnoid hemorrhage. *Crit Rev Neurosurg* 4:147–155
20. Bhattacharjee AK, Kondoh T, Ikeda M, Kohmura E (2002) MMP-9 and EBA immunoreactivity after papaverine mediated opening of the blood–brain barrier. *Neuroreport* 13:2217–2221 doi:10.1097/00001756-200212030-00011
21. Yoshimura S, Hashimoto N, Goto Y, Sampei K, Tsukahara T, Iihara K (1996) Intraarterial infusion of high-concentration papaverine damages cerebral arteries in rats. *Am J Neuroradiol* 17:1891–1894
22. Clyde BL, Firlik AD, Kaufmann AM, Spearman MP, Yonas H (1996) Paradoxical aggravation of vasospasm with papaverine infusion following aneurysmal subarachnoid hemorrhage. Case report. *J Neurosurg* 84:690–695
23. Mathis JM, DeNardo AJ, Thibault L, Jensen ME, Savory J, Dion JE (1994) In vitro evaluation of papaverine hydrochloride incompatibilities: a simulation of intraarterial infusion for cerebral vasospasm. *Am J Neuroradiol* 15:1665–1670
24. Sawada M, Hashimoto N, Tsukahara T, Nishi S, Kaku Y, Yoshimura S (1997) Effectiveness of intra-arterially infused papaverine solutions of various concentrations for the treatment of cerebral vasospasm. *Acta Neurochir (Wien)* 139:706–711 doi:10.1007/BF01420042
25. Oskouian RJ Jr, Martin NA, Lee JH, Glenn TC, Guthrie D, Gonzalez NR et al (2002) Multimodal quantitation of the effects of endovascular therapy for vasospasm on cerebral blood flow, transcranial doppler ultrasonographic velocities, and cerebral artery diameters. *Neurosurgery* 51:30–41 doi:10.1097/00006123-200207000-00005
26. Smith WS, Dowd CF, Johnston SC, Ko NU, DeArmond SJ, Dillon WP et al (2004) Neurotoxicity of intra-arterial papaverine preserved with chlorobutanol used for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. *Stroke* 35:2518–2522 doi:10.1161/01.STR.0000144682.00822.83
27. Numaguchi Y, Zoarski GH (1998) Intra-arterial papaverine treatment for cerebral vasospasm: our experience and review of the literature. *Neurol Med Chir (Tokyo)* 38:189–195 doi:10.2176/nmc.38.189
28. Binaghi S, Colleoni ML, Maeder P, Uske A, Regli L, Dehdashti AR et al (2007) CT angiography and perfusion CT in cerebral vasospasm after subarachnoid hemorrhage. *Am J Neuroradiol* 28:750–758
29. McAuliffe W, Townsend M, Eskridge JM, Newell DW, Grady MS, Winn HR (1995) Intracranial pressure changes induced during papaverine infusion for treatment of vasospasm. *J Neurosurg* 83:430–434
30. Carhuapoma JR, Qureshi AI, Tamargo RJ, Mathis JM, Hanley DF (2001) Intraarterial papaverine-induced seizures: case report and review of the literature. *Surg Neurol* 56:159–163 doi:10.1016/S0090-3019(01)00450-5
31. Elsayed AA, Moran CJ, Cross DT III, Derdeyn CP, Pilgram TK, Milburn JM et al (2006) Effect of intraarterial papaverine and/or angioplasty on the cerebral veins in patients with vasospasm after subarachnoid hemorrhage due to ruptured intracranial aneurysms. *Neurosurg Focus* 21:E16 doi:10.3171/foc.2006.21.3.16
32. Firlik RS, Kaufmann AM, Firlik AD, Jungreis CA, Yonas H (1999) Intra-arterial papaverine for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. *Surg Neurol* 51:66–74 doi:10.1016/S0090-3019(97)00370-4
33. Milburn JM, Moran CJ, Cross DT III, Diringer MN, Pilgram TK, Dacey RG Jr (1998) Increase in diameters of vasospastic intracranial arteries by intraarterial papaverine administration. *J Neurosurg* 88:38–42
34. Murayama Y, Song JK, Uda K, Gobin YP, Duckwiler GR, Tateshima S et al (2003) Combined endovascular treatment for both intracranial aneurysm and symptomatic vasospasm. *Am J Neuroradiol* 24:133–139
35. Polin RS, Hansen CA, German P, Chadduck JB, Kassell NF (1998) Intra-arterially administered papaverine for the treatment of symptomatic cerebral vasospasm. *Neurosurgery* 42:1256–1264 doi:10.1097/00006123-199806000-00031

36. Mindea SA, Yang BP, Bendok BR, Miller JW, Batjer HH (2006) Endovascular treatment strategies for cerebral vasospasm. *Neurosurg Focus* 21:E13
37. Tejada JG, Taylor RA, Ugurel MS, Hayakawa M, Lee SK, Chaloupka JC (2007) Safety and feasibility of intra-arterial nicardipine for the treatment of subarachnoid hemorrhage-associated vasospasm: initial clinical experience with high-dose infusions. *Am J Neuroradiol* 28:844–848
38. Keuskamp J, Murali R, Chao KH (2008) High-dose intraarterial verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. *J Neurosurg* 108:458–463 doi:[10.3171/JNS/2008/108/3/0458](https://doi.org/10.3171/JNS.2008.108.3.0458)
39. Hanggi D, Turowski B, Beseoglu K, Yong M, Steiger HJ (2008) Intra-arterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid hemorrhage: influence on clinical course and cerebral perfusion. *Am J Neuroradiol* 29(6):1053–1060